entertainment -WSS

entertainment

author：Wikipedia 2025-09-28 00:54:06 - browse：7

Alnylam headquarters — Kristoffer Tripplaar/Sipa USA/AP

A group of advisers to the Food and Drug Administration voted in favor of Alnylam Pharmaceuticals’ treatment for a debilitating heart disease Wednesday, but only after a day-long debate challenging whether the drug’s modest observed effects were actually meaningful for patients.

The group of independent experts voted 9-3 that the benefits of Alnylam’s drug, called patisiran, outweighed its risks for patients with ATTR-CM, a progressive disease that leads to fatal heart failure if left untreated. The FDA, which is not required to follow the advice of advisers, is expected to make a final decision on patisiran by Oct. 8.

“It’s like a light wind blowing in favor of patisiran over placebo,” said David Cella, a neurologist at the Northwestern University Feinberg School of Medicine who voted in favor of patisiran. David Moliterno, a cardiologist at the University of Kentucky, added that “the good news in this story is that while there may be a small benefit, it doesn’t look like there’s a signal for harm.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： FDA approves Eli Lilly ulcerative colitis treatment Omvoh

explore

WSS

STAT Health News: mRNA flu shots, Purdue SCOTUS case, etc

AI models in health care face new federal disclosure requirements

First Opinion Podcast: How to protect health care in times of war

FDA has safety concerns on CRISPR

Pregnancy discrimination could be enabled by AI

Readout Newsletter: What happened with Sarepta's Duchenne data

explore

entertainment

hotspot

Malaria cases in Florida and Texas: Here’s what you need to know

Radiology is caught between AI's potential and concern for patients

Moonlake's readout produced a cash windfall. Risks remain

Diversifying clinical trials isn't enough to close racial gaps: study

Sports medicine is finally prioritizing gender equality

The pink breast cancer awareness ribbon needs a redesign

The high cost of giving birth even with insurance

What PEPFAR has meant on the ground in Ukraine

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Patients' immediate access to test results puts radiologists in a bind

knowledge

Americans' trust in science, scientist continues decline: Report

Physician subsidies by hospitals soar in wake of No Surprises Act

AI models in health care face new federal disclosure requirements

Radiology is caught between AI's potential and concern for patients

Chemotherapy shortages won’t get better under Biden’s latest plan

CDC recommends rationing of RSV shot due to shortages

explore

focus

hotspot

explore